atients, 112 (93 percent) had no evidence of cancer -- in spite of 72 being labeled medium to high risk for cancer recurrence. "There were no local recurrences in the areas we treated, and with the ability to re-treat the 7 percent of patients who developed a focus of cancer at a different site in the gland; cryoablation was 100 percent effective in local control of the patient's disease," said Onik. He reported that 85 percent of the men retained sexual function. Of those who did not have previous prostate surgery, all remained continent. "Incontinence becomes a big issue with many patients. For some it's a more important side effect than impotence," said Onik.
According to Onik, the 3-D transperineal biopsy complements the focal cryoablation approach because earlier detection of smaller tumors increases the likelihood that a small tumor can be treated using cryoablation. In his study, Onik restaged 180 patients who had previously undergone TRUS mapping biopsies who were considering conservative management for their cancer. The results showed that 70 percent of the men would have their management changed by the new information provided by mapping. Through mapping, more than 50 percent of men who were diagnosed with cancer on one side of the prostate gland with traditional TRUS biopsy had undetected cancer on the other side as well, he said. Management of prostate cancer is in great part determined by the Gleason score, a cancer ranking method indicating tumor grade and stage and the extent and location of a patient's disease. "When we restaged the men, we found that 22 percent of them experienced an increase in their Gleason score -- meaning that they had a more aggressive cancer than was originally thought from their original biopsy. The 3-D mapping biopsy provided life-saving information," said Onik. "This biopsy technique allows us to map the location of the tumor with tremendous precision and has the potential to greatly affect the decis
'/>"/>
SOURCE Society of Interventional Radiology Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Bay Area Women Sought for Egg Freezing Study2.
Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors3.
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer4.
Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery5.
Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications6.
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer7.
Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors8.
Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease9.
Study Suggests Soy Protein May Reduce Prostate Cancer Risk10.
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer11.
Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial